Literature DB >> 20447141

Stüve-Wiedemann syndrome: long-term follow-up and genetic heterogeneity.

C Jung1, N Dagoneau, G Baujat, M Le Merrer, A David, M Di Rocco, B Hamel, A Mégarbané, A Superti-Furga, S Unger, A Munnich, V Cormier-Daire.   

Abstract

Stüve-Wiedemann syndrome (SWS, OMIM 601559) is a severe autosomal recessive condition caused by mutations in the leukemia inhibitory receptor (LIFR) gene. The main characteristic features are bowing of the long bones, neonatal respiratory distress, swallowing/sucking difficulties and dysautonomia symptoms including temperature instability often leading to death in the first years of life. We report here four patients with SWS who have survived beyond 36 months of age with no LIFR mutation. These patients have been compared with six unreported SWS survivors carrying null LIFR mutations. We provide evidence of clinical homogeneity of the syndrome in spite of the genetic heterogeneity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447141     DOI: 10.1111/j.1399-0004.2009.01314.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  14 in total

1.  Intragenic Deletion in the LIFR Gene in a Long-Term Survivor with Stüve-Wiedemann Syndrome.

Authors:  Júlia Hatagami Marques; Guilherme Lopes Yamamoto; Larissa de Cássia Testai; Alexandre da Costa Pereira; Chong Ae Kim; Maria R Passos-Bueno; Débora Romeo Bertola
Journal:  Mol Syndromol       Date:  2015-05-27

2.  Cardiotrophin-like cytokine (CLCF1) modulates mesenchymal stem cell osteoblastic differentiation.

Authors:  Sarah Nahlé; Sarah Pasquin; Véronique Laplante; François Rousseau; Mukut Sharma; Jean-François Gauchat
Journal:  J Biol Chem       Date:  2019-06-27       Impact factor: 5.157

3.  Effects of leukemia inhibitory receptor gene mutations on human hypothalamo-pituitary-adrenal function.

Authors:  Tulay Guran; Omer Guran; Cem Paketci; Osman Kipoglu; Irfan Firat; Serap Turan; Zeynep Atay; Belma Haliloglu; Abdullah Bereket
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

4.  Mild Campomelic Dysplasia: Report on a Case and Review.

Authors:  S Corbani; E Chouery; B Eid; N Jalkh; J Abou Ghoch; A Mégarbané
Journal:  Mol Syndromol       Date:  2011-01-10

5.  High diagnostic yield of clinical exome sequencing in Middle Eastern patients with Mendelian disorders.

Authors:  Tarunashree Yavarna; Nader Al-Dewik; Mariam Al-Mureikhi; Rehab Ali; Fatma Al-Mesaifri; Laila Mahmoud; Noora Shahbeck; Shenela Lakhani; Mariam AlMulla; Zafar Nawaz; Patrik Vitazka; Fowzan S Alkuraya; Tawfeg Ben-Omran
Journal:  Hum Genet       Date:  2015-06-16       Impact factor: 4.132

6.  Neuropathies of Stüve-Wiedemann Syndrome due to mutations in leukemia inhibitory factor receptor (LIFR) gene.

Authors:  Alexandra E Oxford; Cheryl L Jorcyk; Julia Thom Oxford
Journal:  J Neurol Neuromedicine       Date:  2016

7.  Differential secretion of the mutated protein is a major component affecting phenotypic severity in CRLF1-associated disorders.

Authors:  Jana Herholz; Alessandra Meloni; Mara Marongiu; Francesca Chiappe; Manila Deiana; Carmen Roche Herrero; Giuseppe Zampino; Hanan Hamamy; Yusra Zalloum; Per Erik Waaler; Giangiorgio Crisponi; Laura Crisponi; Frank Rutsch
Journal:  Eur J Hum Genet       Date:  2011-02-16       Impact factor: 4.246

Review 8.  Stüve-Wiedemann Syndrome: Update on Clinical and Genetic Aspects.

Authors:  Débora Romeo Bertola; Rachel S Honjo; Wagner A R Baratela
Journal:  Mol Syndromol       Date:  2016-03-16

9.  One in three: congenital bent bone disease and intermittent hyperthermia in three siblings with stuve-wiedemann syndrome.

Authors:  Roshan Koul; Adila Al-Kindy; Renjith Mani; Dilip Sankhla; Amna Al-Futaisi
Journal:  Sultan Qaboos Univ Med J       Date:  2013-05-09

Review 10.  Stüve-Wiedemann syndrome: LIFR and associated cytokines in clinical course and etiology.

Authors:  Dawn Mikelonis; Cheryl L Jorcyk; Ken Tawara; Julia Thom Oxford
Journal:  Orphanet J Rare Dis       Date:  2014-03-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.